A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaThomas E. Witzig(Mayo Clinic), Thomas M. Habermann(Mayo Clinic)LeukemiaDecember 7, 201010.1038/leu.2010.226Cited by 299SaveCiteExport RISWatch citationsRelated PapersSecreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19|iScience|2023|17